BEIJING, Aug. 7, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2013.
Second Quarter 2013 Financial Highlights
Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, "We were pleased with our second quarter improvement in the quality of our business highlighted by steady sales growth, improved margins and several operational accomplishments. In the past quarter, market demand for our plasma-based products remained strong, which led to increased human albumin product revenue. In the first half of 2013, despite increased import levels in China of foreign human albumin, domestic pricing across our plasma portfolio remained largely stable as the overall market continues to show steady signs of growth, however we will continue to closely monitor market trends related to albumin import volume, and will adjust our pricing and product shipments accordingly. In the coming quarters, we aim to preserve our margins through transitioning to a more profitable product mix and implementing efficient cost control measures. We were glad to achieve improved plasma utilization efficiency following the launch of Factor VIII products. For the second quarter, sales of Factor VIII contributed approximately 2% of total sales and we expect its sales contribution to gradually increase in the long run."
"During the second quarter, our new plasma station in Cao County, Shandong Province commenced plasma collection operations. Additionally, our Shandong Taibang production facility obtained renewed GMP certification from the China Food and Drug Administration ("CFDA") at the end of June, ahead of schedule. Additionally, in Guizhou, we halted production at this facility on June 1st as planned and remain on track with the facility upgrade plan. We currently expect to resume production at Guizhou Taibang in the first quarter of 2014."
Mr. Gao concluded, "The Company announced that it is has entered into a redemption agreement with Ms. Lin Ling Li, an individual shareholder of the Company and her spouse, pursuant to which the Company agreed to redeem 1,479,704 shares of its common stock, representing approximately 5.49% of the total common stock outstanding on August 2, 2013. The redemption price is $20.00 per share, and the redemption shares will become treasure stock of the Company upon closing of the redemption. We believe this share redemption will improve China Biologic's shareholder structure, enhance shareholder value and benefit other existing shareholders of the company. "
Second Quarter 2013 Financial Performance
Total sales in the second quarter of 2013 were $53.6 million, an increase of 6.2% from $50.5 million in the same quarter of 2012. Excluding foreign currency influence, the increase in sales was primarily attributable to a mix of price and volume increases in certain plasma-based products. During the three months ended June 30, 2013, the prices all of the Company's approved products either increased or remained stable. The price increase for the human albumin products was primarily attributable to the increase of the retail price ceiling announced by the NDRC in January 2013, which came into effect at the beginning of February, enabling the Company to have more flexibility in pricing and to raise ex-factory prices in certain regional markets. The average price for human immunoglobulin for intravenous injection ("IVIG") products remained stable as compared to the prior year period.
During the second quarter of 2013, human albumin products and IVIG products remained the largest two sales contributors.
Cost of sales was $16.1 million in the second quarter of 2013, the same with that of the second quarter of 2012. Cost of sales as a percentage of total sales was 30.1%, as compared to 32.0% in the same quarter of 2012.
Gross profit increased by 9.1% to $37.5 million in the second quarter of 2013 from $34.3 million in the same quarter of 2012. Gross margin was 69.9% and 68.0% for the three months ended June 30, 2013 and 2012, respectively. The improvement of our overall gross margin was mainly due to the increased margin of human albumin products and the improved plasma utilization efficiency following the launch of Factor VIII products.
Total operating expenses in the second quarter of 2013 decreased by 6.8% to $12.1 million from $13.0 million in the same quarter of 2012. As a percentage of total sales, total operating expenses decreased to 22.7% from 25.8% in the same quarter of 2012.
Selling expenses in the second quarter of 2013 decreased by 41.4% to $2.4 million from $4.2 million in the same quarter of 2012. As a percentage of total sales, selling expenses were 4.6%, down from 8.3% in the same quarter of 2012. The decrease in selling expenses as a percentage of sales was primarily due to the Company's lower commission rate for certain products, which have been implemented since the second half of 2012. The Company has taken additional steps to further control selling expenses since the second half of 2012. However, the Company carried out a series of promotional activities and conferences for the newly-launched product Factor VIII starting from the second quarter of 2013. As a result, the Company expects selling expenses as a percentage of sales to increase in the following quarters.
General and administrative expenses in the second quarter of 2013 increased by 11.8% to $8.9 million from $7.9 million in the same quarter of 2012. As a percentage of total sales, general and administrative expenses were 16.5% and 15.7% in the second quarter of 2013 and 2012, respectively. The increase in G&A expenses was mainly due to higher payroll expenses and employee benefits, an increase in share-based compensation and an increase in legal expenses related to the corporate defense against the proposed share acquisition by Shanghai RAAS Blood Products Co., Ltd., a public company listed on the Shenzhen Stock Exchange and a direct competitor of the Company in China.
Research and development expenses in the second quarter of 2013 were $835 thousand, representing a decrease of 10.1% from $929 thousand in the same quarter of 2012. As a percentage of total sales, research and development expenses for the three months ended June 30, 2013 and 2012 were 1.6% and 1.8%, respectively.
Income from operations for the three months ended June 30, 2013 was $25.3 million, an increase of 18.8% from $21.3 million in the same period of 2012. Operating margin increased to 47.2% in the reporting quarter from 42.2% in the same quarter of 2012.
Income tax expense in the second quarter of 2013 was $3.7 million, as compared to $3.3 million in the same quarter of 2012, representing an increase of 12.4%. The effective income tax rates were 14.0% and 14.5% for the three months ended June 30, 2013 and 2012, respectively.
Net income attributable to the Company increased by 25.9% to $16.2 million in the second quarter of 2013, from $12.8 million in the same quarter of 2012. Net margins were 30.2% and 25.4% for the three months ended June 30, 2013 and 2012, respectively. Fully diluted net income per share was $0.57, as compared to $0.46 in the second quarter of 2012.
Non-GAAP adjusted net income attributable to the Company was $17.4 million or $0.62 per diluted share in the second quarter of 2013, compared to $13.3 million or $0.50 per diluted share in the same quarter of 2012.
Non-GAAP adjusted net income and diluted earnings per share for the three months ended June 30, 2013 excluded $1.2 million of non-cash employee share-based compensation expenses.
First Half 2013 Financial Performances
Total sales in the first half of 2013 were $107.6 million, an increase of 10.2% from $97.7 million in the same period of 2012. The increase in sales was primarily attributable to a mix of price and volume increases in certain plasma-based products.
As a percentage of total sales, sales from human albumin products and IVIG products were 40.2% and 43.5%, respectively, for the six months ended June 30, 2013.
Cost of sales increased slightly to $32.7 million in the first half of 2013, from $31.8 million in the same period of 2012. Cost of sales as a percentage of total sales was 30.4%, as compared to 32.6% in the same period of 2012.
Gross profit increased by 13.7% to $74.9 million in the first half of 2013 from $65.8 million in the same period of 2012. Gross margin increased to 69.6% in the first half of 2013 from 67.4% in the same period of 2012. The improvement of the Company's overall gross margin was mainly due to the improved gross margin of human albumin products as a result of price increases and the improved utilization efficiency of plasma following the launch of Factor VIII products.
Total operating expenses in the first half of 2013 decreased by 8.3% to $23.6 million from $25.7 million in the same period of 2012. The decrease of total operating expenses was mainly due to a significant decrease in the selling expenses, partially offset by an increase in the general and administrative expenses. As a percentage of total sales, total operating expenses decreased to 21.9% for the six months ended June 30, 2013, from 26.3% in the same period of 2012.
Income from operations for the six months ended June 30, 2013 was $51.3 million, an increase of 27.8% from $40.1 million in the same period of 2012.
Income tax expense in the first half of 2013 was $8.4 million, as compared to $6.5 million in the same period of 2012. The effective income tax rates were 15.7% and 14.9% for the six months ended June 30, 2013 and 2012, respectively. The tax rate applicable to the Company's major operating subsidiaries in the PRC for 2012 and 2013 is 15%.
Net income attributable to the Company increased by 20.5% to $31.1 million for the six months ended June 30, 2013, from $25.8 million in the same period of 2012. Net margins were 28.9% and 26.4% for the six months ended June 30, 2013 and 2012, respectively.
Non-GAAP adjusted net income attributable to the Company was $33.8 million or $1.21 per diluted share for the six months ended June 30, 2013 compared with $26.0 million or $0.98 per diluted share in the same period of 2012.
Non-GAAP adjusted net income and diluted earnings per share in the six months ended June 30, 2013 excluded $2.7 million of non-cash employee share-based compensation expenses.
As of June 30, 2013, the Company had cash and cash equivalents of $147.3 million, compared to $129.6 million as of December 31, 2012.
Net cash provided by operating activities for the six months ended June 30, 2013 was $37.9 million, as compared to $32.1 million for the same period of 2012.
Outlook
For the full year of 2013, the Company reiterates its full year financial forecast of total sales in the range of $195 million to $205 million and full year non-GAAP adjusted net income in the range of $50 million to $53 million. This guidance assumes the production suspension at the Company's Guizhou facility, only organic growth and excludes acquisitions and necessarily assumes no significant adverse product price changes during 2013. Please note that the Company's 2013 financial outlook may be subject to change depending on market conditions and the GMP upgrade status at the Company's Guizhou Taibang facility.
This forecast reflects the Company's current and preliminary views, which are subject to change.
Conference Call
The Company will host a conference call at 7:30 am, Eastern Time on Wednesday, August 7, 2013, which is 7:30 pm, Beijing Time on August 7, 2013, to discuss second quarter 2013 results and answer questions from investors. Listeners may access the call by dialing 1-480-629-9664.
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com.
A replay of the call will be available through August 21, 2013 by dialing 1-858-384-5517, access code: 4633951.
About China Biologic Products, Inc.
China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.
Non-GAAP Disclosure
This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options and restricted shares granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of warrants. To supplement the Company's unaudited condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
Safe Harbor Statement
This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.
Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected operating and financial performance in 2013, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com
|
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES |
|||||||||||||
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME |
|||||||||||||
|
For the three months ended |
For the six months ended |
||||||||||||
|
June 30, |
June 30, |
June 30, |
June 30, |
||||||||||
|
2013 |
2012 |
2013 |
2012 |
||||||||||
|
Sales |
$ |
53,580,523 |
$ |
50,466,339 |
$ |
107,612,255 |
$ |
97,693,800 |
|||||
|
Cost of sales |
16,122,262 |
16,130,889 |
32,739,020 |
31,846,616 |
|||||||||
|
Gross profit |
37,458,261 |
34,335,450 |
74,873,235 |
65,847,184 |
|||||||||
|
Operating expenses |
|||||||||||||
|
Selling expenses |
2,441,727 |
4,165,242 |
4,278,120 |
8,991,349 |
|||||||||
|
General and administrative expenses |
8,866,071 |
7,932,372 |
17,553,168 |
15,078,166 |
|||||||||
|
Research and development expenses |
835,150 |
929,489 |
1,748,242 |
1,640,077 |
|||||||||
|
Income from operations |
25,315,313 |
21,308,347 |
51,293,705 |
40,137,592 |
|||||||||
|
Other income /(expenses) |
|||||||||||||
|
Equity in income of an equity method investee |
610,997 |
451,891 |
739,945 |
1,474,303 |
|||||||||
|
Change in fair value of derivative liabilities |
- |
559,758 |
- |
1,769,140 |
|||||||||
|
Interest expense |
(198,739) |
(157,635) |
(434,913) |
(766,198) |
|||||||||
|
Interest income |
995,757 |
765,717 |
1,643,819 |
1,309,112 |
|||||||||
|
Other expenses, net |
- |
(1,797) |
- |
(102,786) |
|||||||||
|
Total other income, net |
1,408,015 |
1,617,934 |
1,948,851 |
3,683,571 |
|||||||||
|
Earnings before income tax expense |
26,723,328 |
22,926,281 |
53,242,556 |
43,821,163 |
|||||||||
|
Income tax expense |
3,745,649 |
3,333,616 |
8,352,551 |
6,510,331 |
|||||||||
|
Net income |
22,977,679 |
19,592,665 |
44,890,005 |
37,310,832 |
|||||||||
|
Less: Net income attributable to noncontrolling interest |
6,815,753 |
6,753,894 |
13,812,219 |
11,514,755 |
|||||||||
|
Net income attributable to China Biologic Products, Inc. |
$ |
16,161,926 |
$ |
12,838,771 |
$ |
31,077,786 |
$ |
25,796,077 |
|||||
|
Net income per share of common stock: |
|||||||||||||
|
Basic |
$ |
0.60 |
$ |
0.50 |
$ |
1.15 |
$ |
1.00 |
|||||
|
Diluted |
$ |
0.57 |
$ |
0.46 |
$ |
1.11 |
$ |
0.90 |
|||||
|
Weighted average shares used in computation: |
|||||||||||||
|
Basic |
26,880,459 |
25,875,164 |
26,833,262 |
25,738,145 |
|||||||||
|
Diluted |
28,067,303 |
26,627,160 |
27,967,080 |
26,581,824 |
|||||||||
|
Net income |
$ |
22,977,679 |
$ |
19,592,665 |
$ |
44,890,005 |
$ |
37,310,832 |
|||||
|
Other comprehensive income : |
|||||||||||||
|
Foreign currency translation adjustment, net of nil income taxes |
4,428,715 |
136,178 |
5,825,256 |
1,313,135 |
|||||||||
|
Comprehensive income |
27,406,394 |
19,728,843 |
50,715,261 |
38,623,967 |
|||||||||
|
Less: Comprehensive income attributable to noncontrolling interest |
7,723,790 |
6,750,933 |
14,882,947 |
11,766,768 |
|||||||||
|
Comprehensive income attributable to China Biologic Products, Inc. |
$ |
19,682,604 |
$ |
12,977,910 |
$ |
35,832,314 |
$ |
26,857,199 |
|||||
|
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES |
||||||
|
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||
|
June 30, |
December 31, |
|||||
|
2013 |
2012 |
|||||
|
ASSETS |
||||||
|
Current Assets |
||||||
|
Cash and cash equivalents |
$ |
147,264,448 |
$ |
129,609,317 |
||
|
Accounts receivable, net of allowance for doubtful accounts |
17,821,673 |
11,206,244 |
||||
|
Inventories |
80,907,813 |
75,679,173 |
||||
|
Prepayments and other current assets |
5,503,155 |
5,664,919 |
||||
|
Total Current Assets |
251,497,089 |
222,159,653 |
||||
|
Property, plant and equipment, net |
62,337,422 |
51,325,177 |
||||
|
Intangible assets, net |
3,104,210 |
3,541,582 |
||||
|
Land use rights, net |
6,373,176 |
5,818,709 |
||||
|
Deposits related to land use rights |
16,669,167 |
14,752,574 |
||||
|
Restricted cash |
2,786,502 |
2,912,145 |
||||
|
Equity method investment |
10,937,307 |
10,537,310 |
||||
|
Total Assets |
$ |
353,704,873 |
$ |
311,047,150 |
||
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||||
|
Current liabilities |
||||||
|
Short-term bank loans |
$ |
4,860,000 |
$ |
7,935,000 |
||
|
Accounts payable |
3,018,095 |
2,908,624 |
||||
|
Due to related parties |
4,055,925 |
4,081,624 |
||||
|
Other payables and accrued expenses |
25,895,823 |
25,423,349 |
||||
|
Advance from customers |
2,381,166 |
2,857,420 |
||||
|
Income tax payable |
3,333,141 |
4,513,075 |
||||
|
Total Current Liabilities |
43,544,150 |
47,719,092 |
||||
|
Deferred income |
2,972,700 |
2,912,145 |
||||
|
Other liabilities |
3,410,801 |
2,996,749 |
||||
|
Total Liabilities |
$ |
49,927,651 |
$ |
53,627,986 |
||
|
Stockholders' Equity |
||||||
|
Common stock: par value $0.0001; 100,000,000 shares authorized; 26,952,945 and 26,629,615 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively |
$ |
2,695 |
$ |
2,663 |
||
|
Additional paid-in capital |
67,303,915 |
62,251,731 |
||||
|
Retained earnings |
150,220,786 |
119,143,000 |
||||
|
Accumulated other comprehensive income |
18,826,850 |
14,072,322 |
||||
|
Total equity attributable to China Biologic Products, Inc. |
236,354,246 |
195,469,716 |
||||
|
Noncontrolling interest |
67,422,976 |
61,949,448 |
||||
|
Total Stockholders' Equity |
303,777,222 |
257,419,164 |
||||
|
Commitments and contingencies |
- |
- |
||||
|
Total Liabilities and Stockholders' Equity |
$ |
353,704,873 |
$ |
311,047,150 |
||
|
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES |
||||||
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||
|
For the six months ended |
||||||
|
June 30, |
June 30, |
|||||
|
2013 |
2012 |
|||||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||
|
Net income |
$ |
44,890,005 |
$ |
37,310,832 |
||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||
|
Depreciation |
3,105,739 |
2,281,223 |
||||
|
Amortization |
702,556 |
1,525,267 |
||||
|
(Gain)/loss on sale of property, plant and equipment |
(70,363) |
60,518 |
||||
|
Allowance for doubtful accounts, net |
- |
21,895 |
||||
|
Provision for doubtful accounts - other receivables and prepayments |
6,202 |
35,637 |
||||
|
Write-down of obsolete inventories |
- |
49,703 |
||||
|
Deferred tax expense |
720,679 |
26,341 |
||||
|
Share-based compensation |
3,047,962 |
1,992,958 |
||||
|
Change in fair value of derivative liabilities |
- |
(1,769,140) |
||||
|
Equity in income of an equity method investee |
(739,945) |
(1,474,303) |
||||
|
Change in operating assets and liabilities: |
||||||
|
Accounts receivable |
(6,314,643) |
(4,692,006) |
||||
|
Prepayment and other current assets |
(101,135) |
(292,473) |
||||
|
Inventories |
(3,616,165) |
2,045,191 |
||||
|
Accounts payable |
242,365 |
(1,546,373) |
||||
|
Other payables and accrued expenses |
(2,033,594) |
(2,977,473) |
||||
|
Advance from customers |
(529,984) |
401,393 |
||||
|
Due to related parties |
(140,697) |
1,255,867 |
||||
|
Income tax payable |
(1,260,254) |
(2,185,825) |
||||
|
Net cash provided by operating activities |
$ |
37,908,728 |
$ |
32,069,232 |
||
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||
|
Payment for property, plant and equipment |
(11,912,603) |
(5,098,533) |
||||
|
Payment for intangible assets and land use rights |
(1,137,556) |
(796,707) |
||||
|
Dividend received |
560,980 |
555,310 |
||||
|
Purchase of short-term investment |
- |
(1,348,610) |
||||
|
Proceeds from sale of property, plant and equipment |
83,731 |
- |
||||
|
Net cash used in investing activities |
$ |
(12,405,448) |
$ |
(6,688,540) |
||
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||
|
Proceeds from stock option exercised |
$ |
2,668,916 |
$ |
- |
||
|
Proceeds from warrants exercised |
- |
4,500,000 |
||||
|
Proceeds from short-term bank loans |
4,808,400 |
- |
||||
|
Repayment of short term bank loans |
(8,014,000) |
(11,106,200) |
||||
|
Acquisition of noncontrolling interest |
(1,963,913) |
- |
||||
|
Dividends paid by subsidiaries to noncontrolling interest shareholders |
(8,110,168) |
(4,379,016) |
||||
|
Net cash used in financing activities |
$ |
(10,610,765) |
$ |
(10,985,216) |
||
|
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH |
2,762,616 |
679,914 |
||||
|
NET INCREASE IN CASH |
$ |
17,655,131 |
$ |
15,075,390 |
||
|
Cash and cash equivalents at beginning of period |
129,609,317 |
89,411,835 |
||||
|
Cash and cash equivalents at end of period |
$ |
147,264,448 |
$ |
104,487,225 |
||
|
Supplemental cash flow information |
||||||
|
Cash paid for income taxes |
$ |
8,892,126 |
$ |
8,669,815 |
||
|
Cash paid for interest expense |
$ |
198,900 |
$ |
204,982 |
||
|
Noncash investing and financing activities: |
||||||
|
Acquisition of property, plant and equipment included in payables |
$ |
1,554,828 |
$ |
347,439 |
||
|
Exercise of warrants that were liability classified |
- |
3,641,279 |
||||
|
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
|||||
|
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2013 and 2012 |
|||||
|
For the three months ended |
|||||
|
June 30, |
June 30, |
||||
|
2013 |
2012 |
||||
|
Adjusted Net Income Attributable to the Company - Non GAAP |
$ |
17,406,925 |
$ |
13,309,552 |
|
|
Diluted EPS - Non GAAP |
$ |
0.62 |
$ |
0.50 |
|
|
Non-cash employee stock compensation |
$ |
(1,244,999) |
$ |
(1,030,539) |
|
|
Gain from change in fair value of warrants |
$ |
- |
$ |
559,758 |
|
|
Net Income Attributable to the Company |
$ |
16,161,926 |
$ |
12,838,771 |
|
|
Weighted average number of shares used in computation of Non GAAP diluted EPS |
28,067,303 |
26,627,160 |
|||
|
For the six months ended |
|||||
|
June 30, |
June 30, |
||||
|
2013 |
2012 |
||||
|
Adjusted Net Income Attributable to the Company - Non GAAP |
$ |
33,801,545 |
$ |
26,019,895 |
|
|
Diluted EPS - Non GAAP |
$ |
1.21 |
$ |
0.98 |
|
|
Non-cash employee stock compensation |
$ |
(2,723,759) |
$ |
(1,992,958) |
|
|
Gain from change in fair value of warrants |
$ |
- |
$ |
1,769,140 |
|
|
Net Income Attributable to the Company |
$ |
31,077,786 |
$ |
25,796,077 |
|
|
Weighted average number of shares used in computation of Non GAAP diluted EPS |
27,967,080 |
26,581,824 |
|||